Lattanzi, Simona http://orcid.org/0000-0001-8748-0083
Chiesa, Valentina
Di Gennaro, Giancarlo
Ferlazzo, Edoardo
Labate, Angelo
La Neve, Angela
Meletti, Stefano
Di Bonaventura, Carlo
Audenino, Daniela
Boero, Giovanni
Cianci, Vittoria
Coletti Moja, Mario
Cumbo, Eduardo
Dainese, Filippo
Didato, Giuseppe
Fallica, Elisa
Giordano, Alfonso
Le Piane, Emilio
Panebianco, Mariangela
Piccioli, Marta
Pignatta, Pietro
Puligheddu, Monica
Pulitano, Patrizia
Ranzato, Federica
Renna, Rosaria
Rosati, Eleonora
Vergine, Stella
,
Funding for this research was provided by:
Università Politecnica delle Marche
Article History
Received: 27 January 2024
Accepted: 19 March 2024
First Online: 1 April 2024
Change Date: 11 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10072-024-07526-4
Declarations
:
: Not applicable.
: Simona Lattanzi has received speaker’s or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, Medscape, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, GW Pharmaceuticals, and Rapport Therapeutics outside the submitted work.Valentina Chiesa received speaker and advisory board honoraria from Angelini Pharma, Eisai Pharma, GW, UCB Pharma.Giancarlo Di Gennaro received speaker and advisory board honoraria from Arvelle Therapeutics, UCB Pharma, Eisai Pharma, Angelini Pharma, GW Pharmaceuticals.Edoardo Ferlazzo received speaker and advisory board honoraria from Arvelle Therapeutics, UCB Pharma, Eisai Pharma, Angelini Pharma.Angelo Labate declares no conflict of interest.Angela La Neve has received speaker’s or consultancy fees from Eisai, Mylan, Sanofi, Bial, GW, UCB Pharma, Arvelle Therapeutics, Angelini Pharma, and Neuraxpharma.Stefano Meletti received research grant support from the Ministry of Health (MOH) and Ministry of University and Research (MUR) and has received personal compensation as scientific advisory board member and consultancy for UCB, Jazz Pharmaceuticals, and EISAI outside the submitted work.Carlo Di Bonaventura has received consulting fees or speaker honoraria from UCB Pharma, Eisai, Angelini, JAZZ Pharmaceuticals, Bial, and Lusopharma.